Table 1 |
|||
|
Demographic and serological profiles of patients with SLE |
|||
|
Characteristic |
SLE patients |
Anti-NPM antibodies |
|
|
(n = 82) |
Positive (n = 23) |
Negative (n = 59) |
|
|
|
|||
|
Age, years (mean ± SD) |
38.3 ± 12.3 |
39.8 ± 14.9 |
37.8 ± 11.5 |
|
Females |
73 (89.0) |
18* |
55 |
|
Males |
9 (10.8) |
5* |
4 |
|
aCL |
32 (39) |
15 (65.2)** |
17 (28.8)** |
|
ANA-positive |
66 (80.5) |
23 (100) |
43 (72.8) |
|
Anti-DNA |
46 (56) |
13 (56.5) |
33 (55.9) |
|
Anti-β2GPI |
15 (18.3) |
5 (21.7) |
10 (16.9) |
|
Anti-β2GPI-CL+ |
12 (14.6) |
3 (13) |
9 (15.2) |
|
|
|||
|
aCL, anti-cardiolipin; ANA, anti-nuclear antibodies; β2GPI, β2-glycoprotein I; CL, cardiolipin; NPM, nucleophosmin; SLE, systemic lupus erythematosus. Values are n (%) unless indicated otherwise. * χ2 = 2.4; P = 0.12. ** χ2 = 9.2; P = 0.002. |
|||
|
Lartigue et al. Arthritis Research & Therapy 2005 7:R1394 doi:10.1186/ar1838 |
|||
